Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Five Patent Applications Related to RNAi: Feb 8, 2007

Title: Inhibition of Syk Kinase Expression
Number: 7,173,015
Filed: July 1, 2004
Lead Inventor: Alan Schreiber, University of Pennsylvania (ZaBeCor)
The invention “relates, in general, to Syk kinase and, in particular, to a method of inhibiting Syk kinase expression using small interfering RNA,” according to the patent’s abstract.

Title: Gene Therapy of HBV Infection Via Adeno-Associated Viral Vector-Mediated Long-Term Expression of Small Hairpin RNA
Number: 20070027099
Filed: June 12, 2006
Lead Inventor: Marie Lin, Nanfang Medical University
“The invention provides a vector comprising an AAV-shRNA vector,” the patent application’s abstract states. “The vector is preferably rAAV-151i/1694i. The invention also provides a method of suppressing or inhibiting HBV replication in liver cells infected therewith, comprising administering an amount of an AAVB-shRNA vector effective to suppress, inhibit, or reduce HBV replication.”

Title: Small Interfering RNA with Improved Activity
Number: 20070027097
Filed: July 28, 2005
Inventor: David Lewis, Mirus
The patent application, its abstract states, covers “chemically modified small interfering RNAs. …Combinations of 2'-hydroxyl substitutions on the nucleotide riboses are shown to increase the longevity and extent of target gene knockdown in mammalian cells.”

Title: Method and System for Identifying microRNA Targets and Synthesizing Novel microRNAs and Uses of the Same
Number: 20070026403
Filed: July 15, 2004 PCT Filed: July 15, 2004
Lead Inventor: Artemis Hatzigeorgiou, University of Pennsylvania
The patent application, its abstract states, covers “method of identifying a microRNA-recognition element and of generating microRNAs. … System and computer programs for performing such methods are disclosed [in the application also, as are] … recombinant nucleic acid molecule comprising a heterologous coding sequences and one or more MREs,”
The application further claims “isolated nucleic acid molecule comprising one or more MRE sequences and being free of a coding sequence operably linked to regulatory elements,” the abstract states. “MicroRNA generated by methods of the invention and the use of the microRNAs to downregulate gene expression are [also] disclosed.”

Title: Modulation of Gene Expression Associated with Inflammation Proliferation and Neurite Outgrowth Using Nucleic Acid-Based Technologies
Number: 20070026394
Filed: April, 3 2002 PCT Filed: April 3, 2002
Lead Inventor: Lawrence Blatt, Sirna Therapeutics (Merck)
The invention relates to “nucleic acid molecules, including antisense, enzymatic nucleic acid molecules, and RNA interference molecules … which modulate the expression of prostaglandin D2 (PTGDS), prostaglandin D2 receptor (PTGDR), adenosine receptor, NOGO and NOGO receptor, and IKK genes, such as IKK-gamma, IKK-alpha, or IKK-beta, and PKR genes,” the patent application’s abstract states.

Title: RNAi Expression Constructs
Number: 20070025969
Filed: Feb. 3, 2006
Lead Inventor: Petrus Roelvink, Benitec
The invention “provides compositions and methods suitable for expressing 1-x RNAi agents against a gene or genes in cells, tissues, or organs of interest in vitro and in vivo so as to treat diseases or disorders,” according to the patent application’s abstract.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.